Vitiligo and anti-tumor necrosis factors: Cases report

Therapie. 2021 Sep-Oct;76(5):504-507. doi: 10.1016/j.therap.2020.11.003. Epub 2020 Nov 17.

Authors

Nada Jaouad¹, Kawther Ben Abdelghani², Meriem Sellami², Fadoua Khadiri³, Bouchra Amine⁴, Imane Elbinoune⁴, Alia Fazaa², Ahmed Laatar², Rachid Bahiri⁴

Affiliations

¹ Service of Rheumatology A, El Ayachi Hospital, University Mohamed V Rabat, 11150 Salé, Morocco. Electronic address: j.nada92@gmail.com.
² Mongi Slim Hospital, Faculty of medicine, University of Tunis EL Manar, 2046 Tunis, Tunisia.
³ Poison Control and Pharmacovigilance Center, 10100 Rabat, Morocco.
⁴ Service of Rheumatology A, El Ayachi Hospital, University Mohamed V Rabat, 11150 Salé, Morocco.

PMID: 33323190
DOI: 10.1016/j.therap.2020.11.003

No abstract available

Keywords: Anti-tumor necrosis factor-alpha; Spondyloarthritis; Vitiligo.

Publication types

Case Reports
Letter

MeSH terms

Adult
Female
Humans
Male
Tumor Necrosis Factor Inhibitors* / adverse effects
Vitiligo* / chemically induced
Vitiligo* / drug therapy

Substances

Tumor Necrosis Factor Inhibitors